Welcome to our dedicated page for Biorestorative Therapies SEC filings (Ticker: BRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioRestorative Therapies filings document the regulatory record of a Nevada regenerative medicine company listed on the Nasdaq Capital Market under BRTX. Its disclosures cover BRTX-100 clinical development for chronic lumbar disc disease, the ThermoStem metabolic program, the BioCosmeceutical platform, operating results, risk factors, and the use of capital for research, development, commercialization and working capital.
Recent filings include Form 8-K reports for financial results, Regulation FD presentations, executive compensation actions and material agreements, as well as registration statements for common stock, pre-funded warrants and common stock warrants. Proxy materials describe stockholder voting matters, charter-related proposals, board governance and compensation disclosures.
Registration covers up to 15,285,715 shares of common stock underlying outstanding warrants. This prospectus registers 14,285,715 shares issuable upon exercise of Common Stock Warrants (exercise price $0.35) and 1,000,000 shares issuable upon exercise of Placement Agent Warrants (exercise price $0.4375), each exercisable until February 13, 2031. The filing states 25,478,170 shares outstanding as of April 28, 2026 and a post‑exercise share count of up to 40,763,885 assuming full exercise. The company estimates gross proceeds of $5,437,500 if all warrants are exercised for cash and discloses a cashless exercise feature if registration is not effective.
BioRestorative Therapies, Inc. filed Amendment No. 1 to its Post-Effective Amendment No. 1 to the Form S-1 registration statement (Registration No. 333-293322) on April 27, 2026. This amendment is exhibit-only and files a revised opinion of counsel as Exhibit 5; the prospectus and remaining Part II are unchanged.
The filing lists the registrant's principal office in Melville, New York, identifies Nevada as the state of incorporation, and references multiple exhibits and agreements incorporated by reference, including an At the Market Offering Agreement dated November 6, 2024.
BioRestorative Therapies, Inc. furnished an updated corporate presentation that may be used at conferences and investor meetings. The deck is available on the company’s website and is attached as Exhibit 99.1.
The presentation is furnished under a disclosure item and is not deemed filed or subject to Section 18 liability, nor automatically incorporated into other Securities Act or Exchange Act filings.
BioRestorative Therapies, Inc. files a Post-Effective Amendment to its Form S-1 to register up to 15,285,715 shares of common stock issuable upon exercise of outstanding warrants issued in February 2026.
The amendment incorporates the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updates offering details for the 14,285,715 Common Stock Warrants (exercise price $0.35) and 1,000,000 Placement Agent Warrants (exercise price $0.4375), exercisable through February 13, 2031. The prospectus notes going-concern disclosure and states estimated gross proceeds of $5,437,500 if all warrants are exercised for cash.
BioRestorative Therapies, Inc. is asking stockholders to approve an amendment increasing authorized common shares from 75,000,000 to 1,500,000,000 and to allow adjournment of the special meeting if more proxies are needed. As of April 6, 2026, 25,478,170 common shares were outstanding.
The company cites future capital raising for clinical trials of BRTX-100, its ThermoStem program, biocosmeceuticals development, employee plans, and securities conversions as key uses for additional shares. It warns that future issuances could dilute existing holders’ ownership and notes it currently lacks preemptive rights for stockholders.
The proxy also discloses that the company received a Nasdaq notice on March 26, 2026 for not meeting the $1.00 minimum bid requirement and has until September 22, 2026 to regain compliance. The board highlights existing anti-takeover provisions but states it has no current plans to use additional shares or preferred stock to entrench management.
BioRestorative Therapies, Inc. is asking stockholders to approve an amendment to increase authorized common shares from 75,000,000 to 1,500,000,000 at a Special Meeting on May 26, 2026. The Board also seeks authority to adjourn the meeting to solicit additional proxies if needed. The record date for voting is April 6, 2026. The proxy materials and the 2025 Form 10-K will be made available to stockholders by April 13, 2026. The Board states it has no definitive plans to issue the newly authorized shares but says additional shares would permit future capital raises and other corporate uses. The company disclosed a Nasdaq notice of noncompliance with the $1.00 minimum bid price and has until September 22, 2026 (an initial 180-day cure period from a March 26, 2026 notice) to regain compliance.
BioRestorative Therapies, Inc. files its annual report describing progress across its cell therapy pipeline and capital raising activities. The company is developing BRTX-100 for chronic lumbar disc disease, a ThermoStem metabolic program, and a commercial biocosmeceuticals line.
BRTX-100 received FDA Fast Track designation, completed enrollment of a 99-patient Phase 2 trial, and showed encouraging blinded data with over 74% of subjects achieving major functional improvement and over 72% reporting substantial pain reduction at 52 weeks without serious safety issues. The FDA also granted a Type B meeting, after which Phase 3 enabling work began.
ThermoStem gained additional patents in Europe, Israel, Japan and is advancing preclinical work using brown fat–derived stem cells. The company raised capital through warrant exercises and multiple equity offerings totaling more than $16 million in gross proceeds, but still reports no significant revenue and expects current funds may not cover planned trials and operations for the year ahead.
BioRestorative Therapies, Inc. filed an amendment to a Schedule 13G/A stating that Todd Hale Morrison beneficially owned 0 shares of the company’s common stock as of the close of business on 02/23/2026.
The filing lists 0.0% ownership and zero voting or dispositive power across all categories, and is signed by the reporting person.
BioRestorative Therapies, Inc. reports that the Reporting Persons may be deemed to beneficially own 922,143 shares of Common Stock, representing 4.1% of the class as of the close of business on 02/18/2026.
The 922,143 shares consist of 857,143 shares issuable upon exercise of one warrant ("Intracoastal Warrant 1") and 65,000 shares issuable upon exercise of a second warrant ("Intracoastal Warrant 2"). The filing states each warrant "contains a blocker provision" limiting exercises to prevent ownership above 4.99%.